GSK still has a crush on oligonucleotides, sealing the deal with Elsie

Before being swayed by antibody-drug conjugates, one of GSK’s passion projects was oligonucleotides. As part of this romance, the British Big Pharma signed a research collaboration with Elsie Biotechnologies last summer, and has now decided to cement the relationship on Valentine’s Day.